Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore a concise 11-minute conference talk from the Cancer Genomics Consortium (CGC) 2024 Annual Meeting where Dayo Shittu evaluates the clinical significance of the TP53 polyadenylation signal-disrupting variant rs78378222-G. Learn about this important genomic alteration and its implications for cancer diagnosis and treatment. The CGC represents clinical cytogeneticists, molecular geneticists, and molecular pathologists dedicated to education and promoting best practices in clinical cancer genomics, with the vision that all cancer patients receive accurate genomic diagnoses to guide appropriate therapy. The organization aims to be the authoritative source for guidance on clinical cancer genomic testing best practices.
